CTRI/2017/10/010050招募中未知
Borderline resectable pancreatic tumors: outcomes of multimodality approach
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1) Radiologically defined borderline resectable pancreatic tumors
排除标准
- •1) Metastatic tumors
- •2) PS 2 and above
- •3) Liver and renal function criteria precluding any form of neoadjuvant treatment
- •4) Previous history of any malignancy, cardiac or respiratory disorder, which precludes any form of neoadjuvant treatment
- •5) Previously treated patient
研究者
相似试验
尚未招募
2 期
Improving preoperative staging in patients with locally resectable pancreatic cancer – a randomised controlled trial comparing 12 month recurrence rate of patients managed with standard preoperative assessment of liver metastases, contrast enhanced CT( computed tomography) to preoperative assessment of liver metastases with Primovist (liver specific contrast) MRI ( magnetic resonance imaging )pancreas adenocarcinomaCancer - PancreaticACTRN12614001287628jai seema bagia24
招募中
不适用
Outcomes of pancreatic cystsPancreatic cysts, pancreatic cystic neoplasms, IPMNPancreascystenNL-OMON29340Academic Medical Center600
招募中
不适用
Pancreatic Locally advanced Irresectable Cancer AblatioN (PELICAN trial)Locally advanced pancreatic cancernon-resectabel pancreatic tumor10017998NL-OMON56404Amsterdam UMC174
招募中
1 期
Successful rate of creation pancreatic cancer organoids by EUS-guided fine needle biopsy samplingpancreatic mass suspected pancreatic cancerorganoid,pancreas,pancreatic cancer,EUS,FNBTCTR20200827007none28
进行中（未招募）
1 期
A study in patients with borderline unresectable pancreatic cancer, where Abraxane and Gemcitabine will be administered with the goal of shrinking tumours to make them operable.ocally advanced pancreatic cancerMedDRA version: 17.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864EUCTR2013-004200-19-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge9